Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 542

1.

White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis.

Wiebenga OT, Schoonheim MM, Hulst HE, Nagtegaal GJ, Strijbis EM, Steenwijk MD, Polman CH, Pouwels PJ, Barkhof F, Geurts JJ.

AJNR Am J Neuroradiol. 2016 Jun;37(6):1030-7. doi: 10.3174/ajnr.A4690. Epub 2016 Mar 10.

2.

Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.

Wattjes MP, Rovira À, Miller D, Yousry TA, Sormani MP, de Stefano MP, Tintoré M, Auger C, Tur C, Filippi M, Rocca MA, Fazekas F, Kappos L, Polman C, Frederik Barkhof, Xavier Montalban; MAGNIMS study group.

Nat Rev Neurol. 2015 Oct;11(10):597-606. doi: 10.1038/nrneurol.2015.157. Epub 2015 Sep 15. Review.

PMID:
26369511
3.

A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.

Kuhle J, Hardmeier M, Disanto G, Gugleta K, Ecsedi M, Lienert C, Amato MP, Baum K, Buttmann M, Bayas A, Brassat D, Brochet B, Confavreux C, Edan G, Färkkilä M, Fredrikson S, Frontoni M, D'Hooghe M, Hutchinson M, De Keyser J, Kieseier BC, Kümpfel T, Rio J, Polman C, Roullet E, Stolz C, Vass K, Wandinger KP, Kappos L; European Long-term Follow-up Study Group in Interferon β-1b in Secondary-progressive Multiple Sclerosis.

Mult Scler. 2016 Apr;22(4):533-43. doi: 10.1177/1352458515594440. Epub 2015 Sep 11.

PMID:
26362898
4.

Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process.

Rovira À, Wattjes MP, Tintoré M, Tur C, Yousry TA, Sormani MP, De Stefano N, Filippi M, Auger C, Rocca MA, Barkhof F, Fazekas F, Kappos L, Polman C, Miller D, Montalban X; MAGNIMS study group.

Nat Rev Neurol. 2015 Aug;11(8):471-82. doi: 10.1038/nrneurol.2015.106. Epub 2015 Jul 7. Review. Erratum in: Nat Rev Neurol. 2015 Aug;11(8):483.

PMID:
26149978
5.

Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice.

Freedman MS, Comi G, De Stefano N, Barkhof F, Polman CH, Uitdehaag BM, Lehr L, Stubinski B, Kappos L.

Mult Scler Relat Disord. 2014 Mar;3(2):147-55. doi: 10.1016/j.msard.2013.07.001. Epub 2013 Jul 31. Review.

6.

Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial.

Kappos L, O'Connor P, Radue EW, Polman C, Hohlfeld R, Selmaj K, Ritter S, Schlosshauer R, von Rosenstiel P, Zhang-Auberson L, Francis G.

Neurology. 2015 Apr 14;84(15):1582-91. doi: 10.1212/WNL.0000000000001462. Epub 2015 Mar 20.

7.

Enhanced axonal metabolism during early natalizumab treatment in relapsing-remitting multiple sclerosis.

Wiebenga OT, Klauser AM, Schoonheim MM, Nagtegaal GJ, Steenwijk MD, van Rossum JA, Polman CH, Barkhof F, Pouwels PJ, Geurts JJ.

AJNR Am J Neuroradiol. 2015 Jun;36(6):1116-23. doi: 10.3174/ajnr.A4252. Epub 2015 Mar 5.

8.

Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.

Vennegoor A, van Rossum JA, Polman CH, Wattjes MP, Killestein J.

Mult Scler. 2015 Oct;21(12):1600-3. doi: 10.1177/1352458514567728. Epub 2015 Feb 6.

PMID:
25662344
9.

Quantifying progression of multiple sclerosis via classification of depth videos.

Kontschieder P, Dorn JF, Morrison C, Corish R, Zikic D, Sellen A, D'Souza M, Kamm CP, Burggraaff J, Tewarie P, Vogel T, Azzarito M, Glocker B, Chin P, Dahlke F, Polman C, Kappos L, Uitdehaag B, Criminisi A.

Med Image Comput Comput Assist Interv. 2014;17(Pt 2):429-37.

PMID:
25485408
10.

Functional brain networks: linking thalamic atrophy to clinical disability in multiple sclerosis, a multimodal fMRI and MEG study.

Tewarie P, Schoonheim MM, Schouten DI, Polman CH, Balk LJ, Uitdehaag BM, Geurts JJ, Hillebrand A, Barkhof F, Stam CJ.

Hum Brain Mapp. 2015 Feb;36(2):603-18. doi: 10.1002/hbm.22650. Epub 2014 Oct 8.

PMID:
25293505
11.

Molecular mechanism underlying the impact of vitamin D on disease activity of MS.

Munger KL, Köchert K, Simon KC, Kappos L, Polman CH, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, Barkhof F, Pleimes D, Sandbrink R, Ascherio A, Pohl C.

Ann Clin Transl Neurol. 2014 Aug;1(8):605-17. doi: 10.1002/acn3.91. Epub 2014 Aug 22.

12.

Toward the use of proxy reports for estimating long-term patient-reported outcomes in multiple sclerosis.

Sonder JM, Balk LJ, van der Linden FA, Bosma LV, Polman CH, Uitdehaag BM.

Mult Scler. 2015 Dec;21(14):1865-71. doi: 10.1177/1352458514544078. Epub 2014 Sep 25.

PMID:
25257617
13.

The clinical meaning of walking speed as measured by the timed 25-foot walk in patients with multiple sclerosis.

Cohen JA, Krishnan AV, Goodman AD, Potts J, Wang P, Havrdova E, Polman C, Rudick RA.

JAMA Neurol. 2014 Nov;71(11):1386-93. doi: 10.1001/jamaneurol.2014.1895.

PMID:
25178496
14.

Multiple sclerosis: current knowledge and future outlook.

Kamm CP, Uitdehaag BM, Polman CH.

Eur Neurol. 2014;72(3-4):132-41. doi: 10.1159/000360528. Epub 2014 Jul 30. Review.

15.

Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.

Vennegoor A, Rispens T, Van Oosten BW, Wattjes MP, Wondergem MJ, Teunissen CE, Van der Kleij D, Uitdehaag BM, Polman CH, Killestein J.

Mult Scler. 2015 Apr;21(4):481-4. doi: 10.1177/1352458514541507. Epub 2014 Jul 30.

PMID:
25078275
16.

Disruption of structural and functional networks in long-standing multiple sclerosis.

Tewarie P, Steenwijk MD, Tijms BM, Daams M, Balk LJ, Stam CJ, Uitdehaag BM, Polman CH, Geurts JJ, Barkhof F, Pouwels PJ, Vrenken H, Hillebrand A.

Hum Brain Mapp. 2014 Dec;35(12):5946-61. doi: 10.1002/hbm.22596. Epub 2014 Jul 22.

PMID:
25053254
17.

Detecting clinically-relevant changes in progressive multiple sclerosis.

Bosma LV, Sonder JM, Kragt JJ, Polman CH, Uitdehaag BM.

Mult Scler. 2015 Feb;21(2):171-9. doi: 10.1177/1352458514540969. Epub 2014 Jul 10.

PMID:
25013153
18.

Bidirectional trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis.

Balk LJ, Steenwijk MD, Tewarie P, Daams M, Killestein J, Wattjes MP, Vrenken H, Barkhof F, Polman CH, Uitdehaag BM, Petzold A.

J Neurol Neurosurg Psychiatry. 2015 Apr;86(4):419-24. doi: 10.1136/jnnp-2014-308189. Epub 2014 Jun 27.

PMID:
24973342
19.

A computer-based screening method for distress in patients with multiple sclerosis: a feasibility study.

Boeschoten RE, Uitdehaag BM, van Oppen P, de Groot V, Collette EH, Bakker KA, Polman CH, Dekker J.

JMIR Res Protoc. 2014 Jun 4;3(2):e29. doi: 10.2196/resprot.3098.

20.

Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study.

O'Connor P, Goodman A, Kappos L, Lublin F, Polman C, Rudick RA, Hauswirth K, Cristiano LM, Forrestal F, Duda P.

Neurology. 2014 Jul 1;83(1):78-86. doi: 10.1212/WNL.0000000000000541. Epub 2014 Jun 4. Erratum in: Neurology. 2014 Aug 19;83(8):773.

21.

Defining the clinical course of multiple sclerosis: the 2013 revisions.

Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B Jr, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH.

Neurology. 2014 Jul 15;83(3):278-86. doi: 10.1212/WNL.0000000000000560. Epub 2014 May 28.

22.

Morphological features of MS lesions on FLAIR* at 7 T and their relation to patient characteristics.

Kilsdonk ID, Lopez-Soriano A, Kuijer JP, de Graaf WL, Castelijns JA, Polman CH, Luijten PR, Geurts JJ, Barkhof F, Wattjes MP.

J Neurol. 2014 Jul;261(7):1356-64. doi: 10.1007/s00415-014-7351-6. Epub 2014 Apr 29.

PMID:
24777693
23.

Structural degree predicts functional network connectivity: a multimodal resting-state fMRI and MEG study.

Tewarie P, Hillebrand A, van Dellen E, Schoonheim MM, Barkhof F, Polman CH, Beaulieu C, Gong G, van Dijk BW, Stam CJ.

Neuroimage. 2014 Aug 15;97:296-307. doi: 10.1016/j.neuroimage.2014.04.038. Epub 2014 Apr 23.

PMID:
24769185
24.

Do patient and proxy agree? Long-term changes in multiple sclerosis physical impact and walking ability on patient-reported outcome scales.

Sonder JM, Balk LJ, Bosma LV, Polman CH, Uitdehaag BM.

Mult Scler. 2014 Oct;20(12):1616-23. doi: 10.1177/1352458514529173. Epub 2014 Apr 7.

PMID:
24710798
25.

Client-centred therapy in multiple sclerosis: more intensive diagnostic evaluation and less intensive treatment.

Eyssen IC, Dekker J, de Groot V, Steultjens EM, Knol DL, Polman CH, Steultjens MP.

J Rehabil Med. 2014 Jun;46(6):527-31. doi: 10.2340/16501977-1797.

26.

Diagnostic value of brain chronic black holes on T1-weighted MR images in clinically isolated syndromes.

Mitjana R, Tintoré M, Rocca MA, Auger C, Barkhof F, Filippi M, Polman C, Fazekas F, Huerga E, Montalban X, Rovira A.

Mult Scler. 2014 Oct;20(11):1471-7. doi: 10.1177/1352458514526083. Epub 2014 Feb 27.

PMID:
24576831
27.

A dam for retrograde axonal degeneration in multiple sclerosis?

Balk LJ, Twisk JW, Steenwijk MD, Daams M, Tewarie P, Killestein J, Uitdehaag BM, Polman CH, Petzold A.

J Neurol Neurosurg Psychiatry. 2014 Jul;85(7):782-9. doi: 10.1136/jnnp-2013-306902. Epub 2014 Jan 28.

PMID:
24474822
28.

Vitamin D as an early predictor of multiple sclerosis activity and progression.

Ascherio A, Munger KL, White R, Köchert K, Simon KC, Polman CH, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, Barkhof F, Pleimes D, Radü EW, Sandbrink R, Kappos L, Pohl C.

JAMA Neurol. 2014 Mar;71(3):306-14. doi: 10.1001/jamaneurol.2013.5993.

29.

Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study.

Freedman MS, De Stefano N, Barkhof F, Polman CH, Comi G, Uitdehaag BM, Casset-Semanaz F, Hennessy B, Lehr L, Stubinski B, Jack DL, Kappos L.

J Neurol. 2014 Mar;261(3):490-9. doi: 10.1007/s00415-013-7222-6. Epub 2014 Jan 12.

30.

Disease course heterogeneity and OCT in multiple sclerosis.

Balk LJ, Tewarie P, Killestein J, Polman CH, Uitdehaag B, Petzold A.

Mult Scler. 2014 Aug;20(9):1198-206. doi: 10.1177/1352458513518626. Epub 2014 Jan 8.

PMID:
24402036
31.

Changes in functional network centrality underlie cognitive dysfunction and physical disability in multiple sclerosis.

Schoonheim MM, Geurts J, Wiebenga OT, De Munck JC, Polman CH, Stam CJ, Barkhof F, Wink AM.

Mult Scler. 2014 Jul;20(8):1058-65. doi: 10.1177/1352458513516892. Epub 2013 Dec 17.

PMID:
24347184
32.

Improved differentiation between MS and vascular brain lesions using FLAIR* at 7 Tesla.

Kilsdonk ID, Wattjes MP, Lopez-Soriano A, Kuijer JP, de Jong MC, de Graaf WL, Conijn MM, Polman CH, Luijten PR, Geurts JJ, Geerlings MI, Barkhof F.

Eur Radiol. 2014 Apr;24(4):841-9. doi: 10.1007/s00330-013-3080-y. Epub 2013 Dec 9.

PMID:
24317461
33.

Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes.

De Stefano N, Comi G, Kappos L, Freedman MS, Polman CH, Uitdehaag BM, Hennessy B, Casset-Semanaz F, Lehr L, Stubinski B, Jack DL, Barkhof F.

J Neurol Neurosurg Psychiatry. 2014 Jun;85(6):647-53. doi: 10.1136/jnnp-2013-306289. Epub 2013 Nov 29.

34.

Indicators for cognitive performance and subjective cognitive complaints in multiple sclerosis: a role for advanced MRI?

Hulst HE, Gehring K, Uitdehaag BM, Visser LH, Polman CH, Barkhof F, Sitskoorn MM, Geurts JJ.

Mult Scler. 2014 Jul;20(8):1131-4. doi: 10.1177/1352458513513969. Epub 2013 Nov 25.

PMID:
24277326
35.

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.

Edan G, Kappos L, Montalbán X, Polman CH, Freedman MS, Hartung HP, Miller D, Barkhof F, Herrmann J, Lanius V, Stemper B, Pohl C, Sandbrink R, Pleimes D; BENEFIT Study Group.

J Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1183-9. doi: 10.1136/jnnp-2013-306222. Epub 2013 Nov 11.

36.

Cognition in MS correlates with resting-state oscillatory brain activity: An explorative MEG source-space study.

Van der Meer ML, Tewarie P, Schoonheim MM, Douw L, Barkhof F, Polman CH, Stam CJ, Hillebrand A.

Neuroimage Clin. 2013 May 13;2:727-34. doi: 10.1016/j.nicl.2013.05.003. eCollection 2013.

37.

Functional brain network analysis using minimum spanning trees in Multiple Sclerosis: an MEG source-space study.

Tewarie P, Hillebrand A, Schoonheim MM, van Dijk BW, Geurts JJ, Barkhof F, Polman CH, Stam CJ.

Neuroimage. 2014 Mar;88:308-18. doi: 10.1016/j.neuroimage.2013.10.022. Epub 2013 Oct 22.

PMID:
24161625
38.

Comparing long-term results of PASAT and SDMT scores in relation to neuropsychological testing in multiple sclerosis.

Sonder JM, Burggraaff J, Knol DL, Polman CH, Uitdehaag BM.

Mult Scler. 2014 Apr;20(4):481-8. doi: 10.1177/1352458513501570. Epub 2013 Sep 9.

PMID:
24019305
39.

Analyzing differences between patient and proxy on Patient Reported Outcomes in multiple sclerosis.

Sonder JM, Holman R, Knol DL, Bosma LV, Polman CH, Uitdehaag BM.

J Neurol Sci. 2013 Nov 15;334(1-2):143-7. doi: 10.1016/j.jns.2013.08.014. Epub 2013 Aug 15.

PMID:
24018128
40.

Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.

Hegen H, Millonig A, Bertolotto A, Comabella M, Giovanonni G, Guger M, Hoelzl M, Khalil M, Killestein J, Lindberg R, Malucchi S, Mehling M, Montalban X, Polman CH, Rudzki D, Schautzer F, Sellebjerg F, Sørensen PS, Deisenhammer F.

Mult Scler. 2014 Apr;20(5):577-87. doi: 10.1177/1352458513503597. Epub 2013 Sep 5.

PMID:
24009164
41.

Sex-specific extent and severity of white matter damage in multiple sclerosis: implications for cognitive decline.

Schoonheim MM, Vigeveno RM, Rueda Lopes FC, Pouwels PJ, Polman CH, Barkhof F, Geurts JJ.

Hum Brain Mapp. 2014 May;35(5):2348-58. doi: 10.1002/hbm.22332. Epub 2013 Aug 24.

PMID:
23982918
42.

Oxysterols and cholesterol precursors correlate to magnetic resonance imaging measures of neurodegeneration in multiple sclerosis.

van de Kraats C, Killestein J, Popescu V, Rijkers E, Vrenken H, Lütjohann D, Barkhof F, Polman CH, Teunissen CE.

Mult Scler. 2014 Apr;20(4):412-7. doi: 10.1177/1352458513499421. Epub 2013 Aug 19.

PMID:
23959711
43.

Cognitive and clinical dysfunction, altered MEG resting-state networks and thalamic atrophy in multiple sclerosis.

Tewarie P, Schoonheim MM, Stam CJ, van der Meer ML, van Dijk BW, Barkhof F, Polman CH, Hillebrand A.

PLoS One. 2013 Jul 31;8(7):e69318. doi: 10.1371/journal.pone.0069318. Print 2013.

44.

Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome.

Nagtegaal GJ, Pohl C, Wattjes MP, Hulst HE, Freedman MS, Hartung HP, Miller D, Montalban X, Kappos L, Edan G, Pleimes D, Beckman K, Stemper B, Polman CH, Sandbrink R, Barkhof F.

Mult Scler. 2014 Feb;20(2):234-42. doi: 10.1177/1352458513494491. Epub 2013 Jul 10.

PMID:
23842212
45.

Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patients.

van Rossum JA, Vennegoor A, Balk L, Uitdehaag BM, Polman CH, Killestein J.

Mult Scler. 2014 Jan;20(1):108-11. doi: 10.1177/1352458513495582. Epub 2013 Jul 4.

PMID:
23828867
46.

Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration.

Kearney H, Rocca MA, Valsasina P, Balk L, Sastre-Garriga J, Reinhardt J, Ruggieri S, Rovira A, Stippich C, Kappos L, Sprenger T, Tortorella P, Rovaris M, Gasperini C, Montalban X, Geurts JJ, Polman CH, Barkhof F, Filippi M, Altmann DR, Ciccarelli O, Miller DH, Chard DT.

Mult Scler. 2014 Jan;20(1):72-80. doi: 10.1177/1352458513492245. Epub 2013 Jun 27.

47.

Progression in disability and regional grey matter atrophy in relapsing-remitting multiple sclerosis.

Hofstetter L, Naegelin Y, Filli L, Kuster P, Traud S, Smieskova R, Mueller-Lenke N, Kappos L, Gass A, Sprenger T, Penner IK, Nichols TE, Vrenken H, Barkhof F, Polman C, Radue EW, Borgwardt SJ, Bendfeldt K.

Mult Scler. 2014 Feb;20(2):202-13. doi: 10.1177/1352458513493034. Epub 2013 Jun 26.

PMID:
23804554
48.

Relevance of spinal cord abnormalities to clinical disability in multiple sclerosis: MR imaging findings in a large cohort of patients.

Lukas C, Sombekke MH, Bellenberg B, Hahn HK, Popescu V, Bendfeldt K, Radue EW, Gass A, Borgwardt SJ, Kappos L, Naegelin Y, Knol DL, Polman CH, Geurts JJ, Barkhof F, Vrenken H.

Radiology. 2013 Nov;269(2):542-52. doi: 10.1148/radiol.13122566. Epub 2013 Jun 4.

PMID:
23737540
49.

PML in a patient treated with dimethyl fumarate from a compounding pharmacy.

van Oosten BW, Killestein J, Barkhof F, Polman CH, Wattjes MP.

N Engl J Med. 2013 Apr 25;368(17):1658-9. doi: 10.1056/NEJMc1215357. No abstract available. Erratum in: N Engl J Med. 2013 May 16;368(20):1950.

50.

Brain atrophy and lesion load predict long term disability in multiple sclerosis.

Popescu V, Agosta F, Hulst HE, Sluimer IC, Knol DL, Sormani MP, Enzinger C, Ropele S, Alonso J, Sastre-Garriga J, Rovira A, Montalban X, Bodini B, Ciccarelli O, Khaleeli Z, Chard DT, Matthews L, Palace J, Giorgio A, De Stefano N, Eisele P, Gass A, Polman CH, Uitdehaag BM, Messina MJ, Comi G, Filippi M, Barkhof F, Vrenken H; MAGNIMS Study Group.

J Neurol Neurosurg Psychiatry. 2013 Oct;84(10):1082-91. doi: 10.1136/jnnp-2012-304094. Epub 2013 Mar 23.

PMID:
23524331

Supplemental Content

Loading ...
Support Center